Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormali...
Main Authors: | Nikhil Agrawal, Arjun Khunger, Pankit Vachhani, Teresa A. Colvin, Alexander Hattoum, Edward Spangenthal, Anne B. Curtis, Grace K. Dy, Marc S. Ernstoff, Igor Puzanov |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2019-03-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/498985 |
Similar Items
-
Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020-04-01) -
A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors
by: Jessica Castrillon Lal, et al.
Published: (2021-05-01) -
Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy
by: Robin Jacob, MD, et al.
Published: (2020-11-01) -
Immune checkpoint inhibitor myocarditis: a systematic case study
by: E. A. Kushnareva, et al.
Published: (2020-12-01) -
Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice
by: Siqi Li, et al.
Published: (2021-01-01)